Homocyst(e)ine and Coronary Heart Disease Brahmajee K. NallamothuA. Mark FendrickGilbert S. Omenn Review Article 22 September 2012 Pages: 429 - 442
Standardisation of Costs Jan B. OostenbrinkMarc A. KoopmanschapFrans F. H. Rutten Review Article 22 September 2012 Pages: 443 - 454
Health-Related Quality of Life and Cost Impact of Irritable Bowel Syndrome in a UK Primary Care Setting Ron L. AkehurstJohn E. BrazierStephen J. Walters Original Research Article 22 September 2012 Pages: 455 - 462
Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values GĂ©rard DuruJean Paul AurayNicolas Nicoloyannis Original Research Article 22 September 2012 Pages: 463 - 473
A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac® in the UK Roben Das GuptaJulian F. Guest Original Research Article 22 September 2012 Pages: 475 - 484
Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium Niels NeymarkThierry GorliaMartine Piccart Original Research Article 22 September 2012 Pages: 485 - 497